FOS and myeloid sarcoma: Our analyses revealed the prominent effect of several TFs such as B‐ATF‐3, members of the AP‐1 complex (FOSB, FRA‐1‐FOSL1, FRA‐2‐FOSL2, JUNB), RUNX factors (RUNX1/RUNX2) and SMAD3, particularly in the context of the MS subtype.